Global patterns of hepatocellular carcinoma management from diagnosis to death: the <scp>BRIDGE</scp> StudyJoong‐Won Park, Morris Sherman, Minshan Chen et al.|Liver International|2015Cited by 1.3k
Brivanib Versus Sorafenib As First-Line Therapy in Patients With Unresectable, Advanced Hepatocellular Carcinoma: Results From the Randomized Phase III BRISK-FL StudyPhilip J. Johnson, Ann‐Lii Cheng, Shukui Qin et al.|Journal of Clinical Oncology|2013Cited by 775
Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trialMasatoshi Kudo, Yasuaki Arai, Hiroshi Aikata et al.|Gut|2019Cited by 720
Construction of the Chinese University Prognostic Index for hepatocellular carcinoma and comparison with the TNM staging system, the Okuda staging system, and the Cancer of the Liver Italian Program staging systemThomas W. T. Leung, Philip J. Johnson, Amanda M. Y. Tang et al.|Cancer|2002Cited by 584
The role of hepatic resection in the treatment of hepatocellular cancerSasan Roayaie, Morris Sherman, Ghalib Jibara et al.|Hepatology|2015Cited by 415